Literature DB >> 21984749

Association between deletion size and important phenotypes expands the genomic region of interest in Phelan-McDermid syndrome (22q13 deletion syndrome).

Sara M Sarasua1, Alka Dwivedi, Luigi Boccuto, Jonathan D Rollins, Chin-Fu Chen, R Curtis Rogers, Katy Phelan, Barbara R DuPont, Julianne S Collins.   

Abstract

BACKGROUND: The clinical features of Phelan-McDermid syndrome (also known as 22q13 deletion syndrome) are highly variable and include hypotonia, speech and other developmental delays, autistic traits and mildly dysmorphic features. Patient deletion sizes are also highly variable, prompting this genotype-phenotype association study.
METHODS: Terminal deletion breakpoints were identified for 71 individuals in a patient cohort using a custom-designed high-resolution oligonucleotide array comparative genomic hybridisation platform with a resolution of 100 bp.
RESULTS: Patient deletion sizes were highly variable, ranging from 0.22 to 9.22 Mb, and no common breakpoint was observed. SHANK3, the major candidate gene for the neurologic features of the syndrome, was deleted in all cases. Sixteen features (neonatal hypotonia, neonatal hyporeflexia, neonatal feeding problems, speech/language delay, delayed age at crawling, delayed age at walking, severity of developmental delay, male genital anomalies, dysplastic toenails, large or fleshy hands, macrocephaly, tall stature, facial asymmetry, full brow, atypical reflexes and dolichocephaly) were found to be significantly associated with larger deletion sizes, suggesting the role of additional genes or regulatory regions proximal to SHANK3. Individuals with autism spectrum disorders (ASDs) were found to have smaller deletion sizes (median deletion size of 3.39 Mb) than those without ASDs (median deletion size 6.03 Mb, p=0.0144). This may reflect the difficulty in diagnosing ASDs in individuals with severe developmental delay.
CONCLUSIONS: This genotype-phenotype analysis explains some of the phenotypic variability in the syndrome and identifies new genomic regions with a high likelihood for causing important developmental phenotypes such as speech delay.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21984749     DOI: 10.1136/jmedgenet-2011-100225

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  55 in total

1.  Epigenetic dysregulation of SHANK3 in brain tissues from individuals with autism spectrum disorders.

Authors:  Li Zhu; Xiaoming Wang; Xin-Lei Li; Aaron Towers; Xinyu Cao; Ping Wang; Rachel Bowman; Hyuna Yang; Jennifer Goldstein; Yi-Ju Li; Yong-Hui Jiang
Journal:  Hum Mol Genet       Date:  2013-11-01       Impact factor: 6.150

2.  Autism Spectrum Disorder, Intellectual Disability, and Delayed Walking.

Authors:  Somer L Bishop; Audrey Thurm; Cristan Farmer; Catherine Lord
Journal:  Pediatrics       Date:  2016-02-03       Impact factor: 7.124

3.  Accelerating Scientific Advancement for Pediatric Rare Lung Disease Research. Report from a National Institutes of Health-NHLBI Workshop, September 3 and 4, 2015.

Authors:  Lisa R Young; Bruce C Trapnell; Kenneth D Mandl; Daniel T Swarr; Jennifer A Wambach; Carol J Blaisdell
Journal:  Ann Am Thorac Soc       Date:  2016-12

4.  Characterizing regression in Phelan McDermid Syndrome (22q13 deletion syndrome).

Authors:  Gillian Reierson; Jon Bernstein; Wendy Froehlich-Santino; Alexander Urban; Carolin Purmann; Sean Berquist; Josh Jordan; Ruth O'Hara; Joachim Hallmayer
Journal:  J Psychiatr Res       Date:  2017-03-16       Impact factor: 4.791

Review 5.  Phelan McDermid Syndrome: From Genetic Discoveries to Animal Models and Treatment.

Authors:  Hala Harony-Nicolas; Silvia De Rubeis; Alexander Kolevzon; Joseph D Buxbaum
Journal:  J Child Neurol       Date:  2015-09-08       Impact factor: 1.987

6.  Autism-Associated Insertion Mutation (InsG) of Shank3 Exon 21 Causes Impaired Synaptic Transmission and Behavioral Deficits.

Authors:  Haley E Speed; Mehreen Kouser; Zhong Xuan; Jeremy M Reimers; Christine F Ochoa; Natasha Gupta; Shunan Liu; Craig M Powell
Journal:  J Neurosci       Date:  2015-07-01       Impact factor: 6.167

7.  Expression of SHANK3 in the Temporal Neocortex of Patients with Intractable Temporal Epilepsy and Epilepsy Rat Models.

Authors:  Yanke Zhang; Baobing Gao; Yan Xiong; Fangshuo Zheng; Xin Xu; Yong Yang; Yida Hu; Xuefeng Wang
Journal:  Cell Mol Neurobiol       Date:  2016-09-03       Impact factor: 5.046

8.  Cerebellar and posterior fossa malformations in patients with autism-associated chromosome 22q13 terminal deletion.

Authors:  Kimberly A Aldinger; Jillene Kogan; Virginia Kimonis; Bridget Fernandez; Denise Horn; Eva Klopocki; Brian Chung; Annick Toutain; Rosanna Weksberg; Kathleen J Millen; A James Barkovich; William B Dobyns
Journal:  Am J Med Genet A       Date:  2012-12-07       Impact factor: 2.802

Review 9.  Modeling autism by SHANK gene mutations in mice.

Authors:  Yong-Hui Jiang; Michael D Ehlers
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

10.  Novel Shank3 mutant exhibits behaviors with face validity for autism and altered striatal and hippocampal function.

Authors:  Thomas C Jaramillo; Haley E Speed; Zhong Xuan; Jeremy M Reimers; Christine Ochoa Escamilla; Travis P Weaver; Shunan Liu; Irina Filonova; Craig M Powell
Journal:  Autism Res       Date:  2016-08-05       Impact factor: 5.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.